Two new studies in IBD genetics show that polygenic risk scores can predict disease severity in Danish patients, and that ancestry-specific variants in Hispanic populations reveal novel risk loci and differential effects of known genes. These findings advance precision medicine by improving risk prediction and highlighting the need for diverse genetic research.
Upstream Bio presented additional Phase 2 VIBRANT trial data showing verekitug reduced nasal polyp scores and congestion in chronic rhinosinusitis patients, while Phase 2 VALIANT trial results demonstrated significant reductions in asthma exacerbations with multiple dosing regimens.
The European Commission has approved GSK's Exdensur (depemokimab) as the first ultra-long-acting biologic for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps, offering twice-yearly dosing based on positive phase 3 trial results.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07341776 |
Steroid Use in Treatment of Allergic Reactions to Food |
RECRUITING | PHASE4 |
| NCT07328984 |
How Long Should we Give Steroids for Patients With Severe PCP |
NOT_YET_RECRUITING | PHASE4 |
| NCT07113834 |
Characteristics of Ankylosing Spondylitis Associated Uveitis |
COMPLETED | |
| NCT02406651 |
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD |
COMPLETED | PHASE1/PHASE2 |
| NCT01079988 |
Study of Therapeutic Options for Subjects Discontinuing Efalizumab and Experiencing Disease Recurrence |
COMPLETED | PHASE4 |
